Product Name: Human MUC1 Antibody (Clivatuzumab, Research Use)
Catalog Number: NBR-0250
Target Name: MUC1
Trade Name: Clivatuzumab
Antibody Drug Description: Yttrium (90 Y) Clivatuzumab Tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate (ADC) designed by Immunomedics, Inc. for the treatment of pancreatic cancer. The antibody part, clivatuzumab (also known as PAM4), which targets mucin 1 (MUC1), is conjugated with the chelating agent 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA), tetraxetan, and radiolabeled with the beta-emitting radioisotope Yttrium-90, a radioisotope which destroys the tumor cells. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: MUC1
Synonyms: ADMCKD; ADMCKD1; CD227; MCD; MCKD; MCKD1; PEM; PUM
Target Description: The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.
Ensembl: ENSG00000185499 
Uniprot: P15941